609154 Disclosed is an anti-human CCR7 antibody that specifically binds to an extracellular domain of human CCR7, wherein the antibody comprises an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation without relying on complement-dependent cell lysis action or antibody-dependent cell-mediated cytotoxicity. The antibodies of the invention contain the structural features as defined below or are produced by one of the following hybridomas R7-01 (deposited as FERM BP-11369) , R7-02 (deposited as FERM BP-11404), R7-05 (deposited as FERN BP-11371), R7-09 (deposited as FERN BP-11372), R7-11 (deposited as FERN BP-11373), R7-18 (deposited as FERN BP-11374), R7-25 (deposited as FERN BP-11375), or R7-47 (deposited as FERM BP-11376) or an antibody which competitively inhibits binding between the anti-human CCR7 antibody as defined herein. Antibody as defined (B1) which comprises the following CDR regions YTFTDYYIN, RVNPGNGGTSYNQRFKG, ARTGTYYNYDRGGFAY, RCSQNIVHINGNTYLE, KVSNRFSGVPDRFS and FQGSHVPHT. Antibody as defined (B2) which comprises the following CDR regions FNIRDDYVH, RIDPANGNTKYGPKFQA, TRSFYDYDLFVP, RSSTGAVTKNNFAN, GNNIRAP and ALWYSNHWV Antibody as defined (B3) which comprises the following CDR regions FNIKDDYIH, RVDPADGNTKYAPNFHD, ARSFYDYDLFAS, RSSTGAVTTSNFAN, SNNKRAP and ALWYSNHWV Antibody as defined (B4) which comprises the following CDR regions FNIKDDYIH, RIDPANGNTKYAPKFQD, ARSFYDYDLFAS, RSSTGAVTTSNFAN, GNNKRAP and ALWYNNHWV Antibody as defined (B5) which comprises the following CDR regions YSFTAYYMH, RVNPNNGGTSYNRKFKD, CARSESDHFYAMD, RSSQSLVHSNGNTYLC, RVSNRFS and FQGSHVPHT Antibody as defined (B6) which comprises the following CDR regions YSFTGYYMH, RVNPNNGGTSYNKKFKV, CARSESNNFYAMD, RSSQSLVHSNGNTYLC, RVSNRFS and FQGSHVPHT Antibody as defined (B7) which comprises the following CDR regions YSITSGYDWHWI, YINYSGSTNYKPSLKS, ARGSYYSYEFAY, KSSQRLLYYSTQKNYLA, WASTRES and QQYYTYPT Antibody as defined (B
